220 related articles for article (PubMed ID: 28051113)
1. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.
Castellanos E; Gel B; Rosas I; Tornero E; Santín S; Pluvinet R; Velasco J; Sumoy L; Del Valle J; Perucho M; Blanco I; Navarro M; Brunet J; Pineda M; Feliubadaló L; Capellá G; Lázaro C; Serra E
Sci Rep; 2017 Jan; 7():39348. PubMed ID: 28051113
[TBL] [Abstract][Full Text] [Related]
2. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
3. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
[TBL] [Abstract][Full Text] [Related]
4. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.
Marcus RK; Geurts JL; Grzybowski JA; Turaga KK; Clark Gamblin T; Strong KA; Johnston FM
Fam Cancer; 2015 Dec; 14(4):641-9. PubMed ID: 26108897
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes.
Paulo P; Pinto P; Peixoto A; Santos C; Pinto C; Rocha P; Veiga I; Soares G; Machado C; Ramos F; Teixeira MR
J Mol Diagn; 2017 Jul; 19(4):502-513. PubMed ID: 28529006
[TBL] [Abstract][Full Text] [Related]
6. The changing approach for identifying hereditary colorectal cancer syndromes.
Laghi L; Ricciardiello L
Nat Rev Gastroenterol Hepatol; 2020 Oct; 17(10):593-594. PubMed ID: 32651554
[No Abstract] [Full Text] [Related]
7. Acceptability of, and Information Needs Regarding, Next-Generation Sequencing in People Tested for Hereditary Cancer: A Qualitative Study.
Meiser B; Storey B; Quinn V; Rahman B; Andrews L
J Genet Couns; 2016 Apr; 25(2):218-27. PubMed ID: 26259529
[TBL] [Abstract][Full Text] [Related]
8. [Molecular genetic methods used in diagnosis of hereditary cancers].
Patócs A
Magy Onkol; 2020 Mar; 64(1):25-31. PubMed ID: 32181759
[TBL] [Abstract][Full Text] [Related]
9. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
Tafe LJ
J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
[TBL] [Abstract][Full Text] [Related]
10. Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
Schenkel LC; Kerkhof J; Stuart A; Reilly J; Eng B; Woodside C; Levstik A; Howlett CJ; Rupar AC; Knoll JHM; Ainsworth P; Waye JS; Sadikovic B
J Mol Diagn; 2016 Sep; 18(5):657-667. PubMed ID: 27376475
[TBL] [Abstract][Full Text] [Related]
11. Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.
Feliubadaló L; Tonda R; Gausachs M; Trotta JR; Castellanos E; López-Doriga A; Teulé À; Tornero E; Del Valle J; Gel B; Gut M; Pineda M; González S; Menéndez M; Navarro M; Capellá G; Gut I; Serra E; Brunet J; Beltran S; Lázaro C
Sci Rep; 2017 Jan; 7():37984. PubMed ID: 28050010
[TBL] [Abstract][Full Text] [Related]
12. Multigene Testing for Hereditary Cancer: When, Why, and How.
Offit K
J Natl Compr Canc Netw; 2017 May; 15(5S):741-743. PubMed ID: 28515260
[TBL] [Abstract][Full Text] [Related]
13. [The progress and prospect of application of genetic testing technology-based gene detection technology in the diagnosis and treatment of hereditary cancer].
He JX; Jiang YF
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Aug; 51(8):772-776. PubMed ID: 28763932
[TBL] [Abstract][Full Text] [Related]
14. [Hereditary cutaneous tumor syndromes].
Hermasch MA; Frank J
Hautarzt; 2019 Jul; 70(7):490-496. PubMed ID: 31143971
[TBL] [Abstract][Full Text] [Related]
15. Hereditary colorectal cancer: more common than you think.
Jasperson KW
Curr Probl Cancer; 2014; 38(6):249-61. PubMed ID: 25497411
[No Abstract] [Full Text] [Related]
16. Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test.
Nguyen KA; Syed JS; Espenschied CR; LaDuca H; Bhagat AM; Suarez-Sarmiento A; O'Rourke TK; Brierley KL; Hofstatter EW; Shuch B
Cancer; 2017 Nov; 123(22):4363-4371. PubMed ID: 28787086
[TBL] [Abstract][Full Text] [Related]
17. Principles of molecular testing for hereditary cancer.
Mighton C; Lerner-Ellis JP
Genes Chromosomes Cancer; 2022 Jun; 61(6):356-381. PubMed ID: 35436018
[TBL] [Abstract][Full Text] [Related]
18. Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle.
Bowles KR; Mancini-DiNardo D; Coffee B; Cox HC; Qian Y; Elias M; Singh N; Judkins T; Leclair B; Roa BB
Future Oncol; 2019 Jan; 15(1):65-79. PubMed ID: 30113232
[TBL] [Abstract][Full Text] [Related]
19. Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing.
Mu W; Lu HM; Chen J; Li S; Elliott AM
J Mol Diagn; 2016 Nov; 18(6):923-932. PubMed ID: 27720647
[TBL] [Abstract][Full Text] [Related]
20. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
LaDuca H; Stuenkel AJ; Dolinsky JS; Keiles S; Tandy S; Pesaran T; Chen E; Gau CL; Palmaer E; Shoaepour K; Shah D; Speare V; Gandomi S; Chao E
Genet Med; 2014 Nov; 16(11):830-7. PubMed ID: 24763289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
